Corix Bioscience, Inc.
CXBS
Other OTC0.00
USD
- -
- -
Corix Bioscience, Inc.
CXBS
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Corix Bioscience, Inc. Corix Bioscience, Inc. (CXBS) operates as an organic biotechnology company focused on the cultivation, harvesting, extraction, research, development, and commercialization of cannabidiol (CBD) oil and related cannabis-based products derived from industrial hemp plants. The company provides CBD oil for a wide variety of medicinal purposes, including potential applications in therapeutics due to its non-psychoactive properties and lack of interference with psychomotor functions; it engages in planting and growing industrial hemp on leased land, proprietary strain development for CBD and industrial hemp, and extraction processes to produce high-purity CBD accounting for up to 40 percent of plant extracts. Corix Bioscience, Inc. targets healthcare, pharmaceutical, and wellness markets with its offerings, maintaining operations primarily in the United States across states including Oregon, California, Nevada, and Arizona. Founded through a name change from American Housing Income Trust, Inc. in June 2017 and headquartered in Phoenix, Arizona, with principal executive offices previously noted in Irvine, California, the company employs a small team with over 50 years of combined experience in CBD and THCV oil cultivation and extraction. In recent developments, Corix Bioscience, Inc. acquired 100 percent of Pharmaceutical Development Corp., Ltd. to enable sales of its proprietary cannabis products; it issued a 10 percent convertible note for $175,000 principal along with warrants in 2017 to support growth initiatives; and the company positions itself for aggressive expansion as a leading CBD provider, though its website currently reflects domain sale status as of 2025.